diabetes

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

Maureen Gannon, PhD, professor of Medicine, Molecular Physiology and Biophysics, and Cell and Developmental Biology, is the recipient of the 2022 Lois Jovanovic Transformative Woman in Diabetes Award presented by the American Diabetes Association (ADA).

Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Vanderbilt Diabetes Day, an annual event that showcases the work of outstanding scientists and researchers in the fields of diabetes, obesity and metabolism was held this month, and it marked the first time many investigators working under the auspices of the Vanderbilt Diabetes Research and Training Center (DRTC) had gathered in one space since the beginning of the COVID-19 pandemic.

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

Seventy-five percent of participants in a diabetes prevention program run by medical students lost at least 5% of their body weight, and many participants also reported less pain and an overall improved quality of life.